PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026JAMA5 citations

The First AI Drug Prescriber

View Full Paper
DADaniel G. AaronCRChristopher Robertson

Key Points

  • This viewpoint examines the integration of AI in clinical care and its implications for drug prescription.
  • Explored the role of AI in clinical settings
  • Discussed the regulatory framework by the US FDA
  • Analyzed legal and public health implications
  • AI has potential to enhance clinical decision-making
  • Policy and regulatory adaptations are necessary
  • Legal frameworks need to address AI-related challenges

Abstract

This Viewpoint explores the entry of AI into clinical care, the role of the US Food and Drug Administration, and the associated legal, public health, and medical implications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Aaron et al. (2026) studied this question.

synapsesocial.com/papers/69df2c01e4eeef8a2a6b1013https://doi.org/10.1001/jama.2026.3533
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Guidance on Responsible Use of AI2025 · 19 citations
  2. 2Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction2008 · 489 citations
  3. 3Reasons for Primary Medication Nonadherence: A Systematic Review and Metric Analysis2018 · 48 citations
  4. 4Cost of Prescription Drug–Related Morbidity and Mortality2018 · 367 citations
  5. 5The silent epidemic of non-adherence – insights from the 2024 a:care congress2025 · 6 citations